NO20076121L - Behandlinger for kardiovaskulaer sykdom - Google Patents

Behandlinger for kardiovaskulaer sykdom

Info

Publication number
NO20076121L
NO20076121L NO20076121A NO20076121A NO20076121L NO 20076121 L NO20076121 L NO 20076121L NO 20076121 A NO20076121 A NO 20076121A NO 20076121 A NO20076121 A NO 20076121A NO 20076121 L NO20076121 L NO 20076121L
Authority
NO
Norway
Prior art keywords
treatments
cardiovascular disease
agents
methods
cardiac dysfunction
Prior art date
Application number
NO20076121A
Other languages
English (en)
Norwegian (no)
Inventor
David Y Liu
Ingrid Langsetmo Parobok
Christopher T Jacob
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of NO20076121L publication Critical patent/NO20076121L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20076121A 2005-05-05 2007-11-27 Behandlinger for kardiovaskulaer sykdom NO20076121L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67849505P 2005-05-05 2005-05-05
US69095705P 2005-06-15 2005-06-15
US73443305P 2005-11-07 2005-11-07
PCT/US2006/017760 WO2006122047A1 (en) 2005-05-05 2006-05-05 Cardiovascular disease therapies

Publications (1)

Publication Number Publication Date
NO20076121L true NO20076121L (no) 2008-02-04

Family

ID=36778299

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20076121A NO20076121L (no) 2005-05-05 2007-11-27 Behandlinger for kardiovaskulaer sykdom
NO20076241A NO20076241L (no) 2005-05-05 2007-12-04 Terapier for vaskulaere sykdommer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20076241A NO20076241L (no) 2005-05-05 2007-12-04 Terapier for vaskulaere sykdommer

Country Status (10)

Country Link
US (3) US20060281668A1 (es)
EP (2) EP1885756A2 (es)
JP (2) JP2008540456A (es)
AU (2) AU2006244148A1 (es)
CA (2) CA2607044A1 (es)
IL (2) IL187113A (es)
MX (2) MX2007013819A (es)
NO (2) NO20076121L (es)
NZ (1) NZ563493A (es)
WO (2) WO2006122046A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098065A2 (en) * 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US20080075666A1 (en) * 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
US9220720B2 (en) 2007-10-18 2015-12-29 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy
US9114151B2 (en) * 2007-10-18 2015-08-25 The United States Of America Dept. Of Veterans Affairs Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria
US9211301B2 (en) 2007-10-18 2015-12-15 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy by improving conduction velocity
US9050350B2 (en) 2007-10-18 2015-06-09 U.S. Department Of Veterans Affairs Method for modulating or controlling connexin 43(Cx43) level of a cell and reducing arrhythmic risk
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
NZ591416A (en) 2008-08-25 2012-11-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
CA2737448A1 (en) * 2008-09-18 2010-03-25 Universitetet I Oslo Use of ctgf as a cardioprotectant
US20110262398A1 (en) * 2010-04-21 2011-10-27 University Of Illinois Cardiac treatment using anti-fibrotic agents
KR101249041B1 (ko) * 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
PL2670411T3 (pl) 2011-02-02 2019-09-30 Excaliard Pharmaceuticals, Inc. Związki antysensowne ukierunkowane na czynnik wzrostu tkanki łącznej (ctgf) do leczenia bliznowców lub blizn przerostowych
DE102012103096A1 (de) * 2012-04-11 2013-10-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Prophylaxe und Behandlung einer Gefäßkalzifizierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
JPH11180895A (ja) 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
US6562618B1 (en) * 1997-12-25 2003-05-13 Japan Tobacco, Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
AU4976599A (en) 1998-07-08 2000-02-01 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
WO2000035939A2 (en) 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
IL151369A0 (en) * 2000-03-09 2003-04-10 Genzyme Corp USE OF TGF-beta ANTAGONISTS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1463531B1 (en) * 2001-12-11 2011-09-28 Fibrogen, Inc. Methods for inhibiting ocular processes
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
NZ549784A (en) 2004-02-11 2008-06-30 Fibrogen Inc Inhibitors of CTGF the manufacture of a medicament for the treatment of diabetic nephropathy

Also Published As

Publication number Publication date
MX2007013819A (es) 2008-02-05
EP1891109A1 (en) 2008-02-27
WO2006122047A1 (en) 2006-11-16
NZ563493A (en) 2010-10-29
NO20076241L (no) 2008-02-04
EP1885756A2 (en) 2008-02-13
WO2006122046A3 (en) 2007-05-31
CA2607044A1 (en) 2006-11-16
US20120039882A1 (en) 2012-02-16
IL187113A (en) 2011-06-30
US20060281667A1 (en) 2006-12-14
IL187115A0 (en) 2008-02-09
MX2007013834A (es) 2008-02-05
JP2008540457A (ja) 2008-11-20
US8088381B2 (en) 2012-01-03
JP2008540456A (ja) 2008-11-20
AU2006244147A1 (en) 2006-11-16
JP5068253B2 (ja) 2012-11-07
IL187113A0 (en) 2008-02-09
US20060281668A1 (en) 2006-12-14
AU2006244148A1 (en) 2006-11-16
CA2606778A1 (en) 2006-11-16
WO2006122046A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
EP1532269A4 (en) 1L1RL-1 AS A MARKER OF CARDIOVASCULAR DISEASES AND THERAPEUTIC TARGET
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
NO20034590D0 (no) Fremgangsmåter for behandling av vaskul¶r sykdom
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
EA200970446A1 (ru) Связывающиеся с альбумином молекулы и их применение
ATE473735T1 (de) Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut
WO2009149486A3 (en) Compounds for treating beta-amyloidoses
EA200870088A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови
WO2009149485A3 (en) Compounds for treating amyloidoses
EA200701995A1 (ru) Способы уменьшения кальцификации
EA200801310A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO20070996L (no) Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser
WO2006109170A3 (en) Combination therapy for treatment of cardiovascular diseases and related conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application